Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.51 |
| ▸ | JAK2 | O60674 | 9/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851002 | 0.88 | RXFP1 (0.44) | JAK1JAK2HSD17B10TACR1 | |
| SCHEMBL10290691 | 0.81 | MAPT (0.52) | JAK1JAK2GPR119TACR1 | |
| SCHEMBL2604312 | 0.76 | USP30 (0.47) | GPR119ALOX15TSHR | |
| SCHEMBL849109 | 0.75 | MEN1 (0.48) | JAK1JAK2 | |
| SCHEMBL13551776 | 0.75 | USP2 (0.42) | JAK1JAK2GPR119 | |
| SCHEMBL851230 | 0.74 | CRBN (0.46) | JAK1JAK2 | |
| SCHEMBL850808 | 0.74 | CRBN (0.48) | JAK1JAK2GPR119 | |
| SCHEMBL13551815 | 0.73 | TACR1 (0.45) | JAK1JAK2GPR119TACR1 | |
| SCHEMBL16302394 | 0.73 | USP30 (0.42) | JAK1JAK2TACR1 | |
| SCHEMBL13551856 | 0.72 | JAK1 (0.46) | JAK1JAK2GPR119HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | JAK1 1218/4885JAK2 81/4885GPR119 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.